NCT03491631: Phase I Study of SHR9146 in Combination With SHR-1210 and With/Without Apatinib in Patients With Advanced Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 1
Drug Category: Therapeutic Antibody, Immunotherapy, Misc Inhibitor, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 70 Years (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Active brain or meningeal metastasis- see trial for details

Comments are closed.

Up ↑